Clinical Report: Survival With Lu-177 PSMA Therapy by Treatment Line

Overview

In this retrospective US cohort of 850 patients with metastatic androgen pathway modulator–resistant prostate cancer treated with Lu-177 PSMA, median clinical time to next treatment was 8.5 months and median overall survival was 13.0 months. Treatment was most often initiated in the third or fourth line. The supplied article does not provide the subgroup survival estimates by treatment line or taxane sequence.

Background

Lu-177 vipivotide tetraxetan is a PSMA-directed radioligand therapy for metastatic prostate cancer. Its initial approval followed VISION trial evidence in patients previously treated with an androgen receptor pathway inhibitor and taxanes; the indication was later broadened to include taxane-naive patients whose disease progressed during ARPI treatment. As use has expanded, the article identifies limited evidence on outcomes according to treatment line and taxane sequencing. This retrospective cohort study assessed survival outcomes across those groups using US oncology records.

Data Highlights

Key Findings

• The retrospective cohort used Flatiron Health electronic health record data from US community and academic practices; eligible diagnoses occurred from June 11, 2013, through May 19, 2025, and data were cut off June 30, 2025.
• Of 27,979 patients with metastatic prostate cancer identified, 850 met the study eligibility criteria, including prior ARPI exposure before Lu-177 PSMA initiation.
• Median clinical TTNT, defined as time from Lu-177 PSMA initiation to subsequent systemic therapy or death, was 8.5 months (95% CI, 8.0–9.2).
• Median clinical OS, measured from Lu-177 PSMA initiation to death from any cause, was 13.0 months (95% CI, 12.0–14.0).
• Lu-177 PSMA was administered in the third or fourth treatment line for 434 patients (51.1%).
• The study analyses were descriptive and did not include hypothesis testing; the supplied article text does not report numerical survival estimates for the treatment-line or taxane-timing subgroups.

Clinical Implications

The reported cohort-level TTNT and OS provide descriptive outcomes for patients with prior ARPI exposure treated with Lu-177 PSMA in US practice settings. Because subgroup estimates are not included in the supplied article text and the analyses were descriptive, the material does not establish comparative outcomes by treatment line or taxane sequence.

Conclusion

In this cohort, median clinical TTNT was 8.5 months and median clinical OS was 13.0 months, with treatment most commonly initiated in the third or fourth line. The supplied results do not quantify survival differences by treatment line or taxane exposure timing.

Related Resources & Content

1. Article source, supplied text, year not stated — Survival With Lu-177 PSMA Therapy in Prostate Cancer: Outcomes by Treatment Line and Taxane Sequence
2. Herrmann et al, The ASCO Post, 2024 — Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer
3. ASCO Publications, 2025 — Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy
4. ASCO Publications — Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.
5. the asco post — LuPSMA vs Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
6. Oncology (Cancer)/Hematologic Malignancies Approval Notifications | FDA
7. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
8. Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure